RT Journal Article
T1 Development of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis
A1 García-Argüello, Segundo Francisco
A1 Lopez-Lorenzo, Beatriz
A1 Cornelissen, Bart
A1 Smith, Graham
K1 Positron emission tomography
K1 Apoptosis
K1 Caspase-3
K1 [18F]ICMT-11
K1 Pyrimidoindolone
K1 Michael acceptor
K1 Neoplasms
K1 Isatin
K1 Tomografía de emisión de positrones
K1 Caspasa-3
K1 Neoplasias
K1 Isatina
AB Insufficient apoptosis is a recognised hallmark of cancer. A strategy to quantitatively measure apoptosis in vivo would be of immense value in both drug discovery and routine patient management. The first irreversible step in the apoptosis cascade is activation of the "executioner" caspase-3 enzyme to commence cleavage of key structural proteins. One strategy to measure caspase-3 activity is Positron Emission Tomography using isatin-5-sulfonamide radiotracers. One such radiotracer is [18F]ICMT-11, which has progressed to clinical application. This review summarises the design and development process for [18F]ICMT-11, suggesting potential avenues for further innovation.
PB MDPI
YR 2020
FD 2020-08-06
LK http://hdl.handle.net/10668/4148
UL http://hdl.handle.net/10668/4148
LA en
NO García-Argüello SF, Lopez-Lorenzo B, Cornelissen B, Smith G. Development of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis. Cancers. 2020 Aug 6;12(8):2191
DS RISalud
RD Apr 12, 2025